2025-522495-84-00RecruitingPhase 1/2
A Clinical study of MK-4716 in people with certain solid tumors (MK-4716-001)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 3 Nov 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 29 (estimated)
- First submitted
- 26 Sept 2025
- Start date
- 14 Jan 2026
- Lead sponsor
- Merck Sharp & Dohme LLC
- Diseases
- Lung cancer
- EU CT number
- 2025-522495-84-00
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 29
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Recruiting |
| Hospital Clinic de Barcelona | Barcelona | Spain | Recruiting |
| Hospital Universitario Fundación Jiménez Díaz | Madrid | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.